Man Group’s Castle Biosciences CSTL Stock Holding History

Man Group’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.16M	Buy	47,138 +35,553	+307%	+$1.16M	﹤0.01%	1777
2025 Q4	$451K	Buy	+11,585	New	+$373K	﹤0.01%	1918
2025 Q2	–	Sell	-14,514	Closed	-$291K	–	2206
2025 Q1	$291K	Buy	14,514 +1,212	+9%	+$30K	﹤0.01%	1943
2024 Q4	$354K	Buy	+13,302	New	+$405K	﹤0.01%	1750
2024 Q3	–	Sell	-9,600	Closed	-$209K	–	2009
2024 Q2	$209K	Sell	9,600 -13,457	-58%	-$300K	﹤0.01%	1882
2024 Q1	$511K	Buy	+23,057	New	+$502K	﹤0.01%	1773

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Man Group's CSTL Position: Q1 2026 in Review

Man Group increased its Castle Biosciences (CSTL) stake by 307% in Q1 2026, buying an estimated $1.16M and bringing the position to 47,138 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #1777.

Man Group first reported a position in CSTL in Q1 2024 and has held it in 6 quarters since. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

Man Group held 47,138 shares of Castle Biosciences worth $1.16M as of Q1 2026.
Man Group bought 35,553 Castle Biosciences shares in Q1 2026, an estimated $1.16M.
Castle Biosciences made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #1777 holding.
Man Group first reported a position in Castle Biosciences in Q1 2024 and has held it in 6 quarters since.
186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.